This article is more than 5 years old. Information may no longer be current.

Bausch & Lomb purchases OTC ocular allergy drug from Alimera Sciences

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Bausch & Lomb has purchased an over-the-counter ocular allergy drug franchise from Alimera Sciences, the companies announced in a joint press release.

Under the transaction, Bausch & Lomb will take control of Alaway (ketotifen fumarate 0.025%), the OTC equivalent to Zaditor (ketotifen fumarate 0.025%, Novartis) that the Food and Drug Administration approved earlier this month.

In addition to marketing the product, Bausch & Lomb hopes to use the drug's technology platform to develop other ocular allergy medications, the release said.

The transaction will allow Alimera to focus on Medidur, the company's phase 3 steroidal drug delivery system being developed for treating diabetic macular edema, said Dan Myers, Alimera's president and chief executive, in the release.